Table 3 Clinicopathologic characteristics according to residual tumor after surgery
Characteristics | No gross residual (n = 23, %) | Any residual tumor (n = 9, %) | P-value |
|---|---|---|---|
Age at diagnosis, years | 0.360 | ||
Median (range) | 56 (34–77) | 52 (43–70) | |
Menopausal status | 0.682 | ||
Premenopause | 6 (26.1) | 3 (33.3) | |
Postmenopause | 17 (73.9) | 6 (66.7) | |
Histologic subtype | 0.798 | ||
Endometrioid | 12 (52.2) | 6 (66.7) | |
Serous | 4 (17.4) | 1 (11.1) | |
Clear cell | 1 (4.3) | 0 | |
Carcinosarcoma | 4 (17.4) | 2 (22.2) | |
Others | 2 (8.7) | 0 | |
Grade | 0.712 | ||
Low | 7 (30.4) | 4 (44.4) | |
High | 5 (21.8) | 2 (22.2) | |
Not applicable | 11 (47.8) | 3 (33.3) | |
FIGO stage | 0.181 | ||
IIIC | 4 (17.4) | 0 | |
IVB | 19 (82.6) | 9 (100) | |
CA-125 at diagnosis, IU/ml | 0.417 | ||
Median (range) | 144 (8.6–3489.0) | 474 (24.7–3440.0) | |
CA-125 after NAC, IU/ml | 0.417 | ||
Median (range) | 18.6 (7.0–391.0) | 43.1 (15.0–1490.0) | |
NAC regimen | 0.477 | ||
Paclitaxel-carboplatin | 16 (69.6) | 9 (100) | |
Doxorubicin-cisplatin | 2 (8.7) | 0 | |
Paclitaxel-cisplatin-bevacizumab | 2 (8.7) | 0 | |
Ifosfamide-cisplatin | 2 (8.7) | 0 | |
Etoposide-cisplatin | 1 (4.3) | 0 | |
Number of NAC cycles | 0.296 | ||
Median (range) | 6 (2–12) | 4 (2–9) | |
2–3 | 8 (34.8) | 3 (33.3) | |
4–6 | 5 (21.7) | 5 (55.6) | |
≥7 | 10 (43.5) | 1 (11.1) | |
Response to NAC | 0.008 | ||
CR | 2 (8.7) | 0 | |
PR | 20 (87.0) | 4 (44.4) | |
SD | 1 (4.3) | 3 (33.3) | |
PD | 0 | 2 (22.2) |